Stemrx Biosciences has introduced an innovative Micro Dose Infusion Therapy, a groundbreaking treatment designed to target the root causes of diabetes and related metabolic disorders.
In a press statement on Tuesday, the company informed that this therapy administers insulin as a hormone rather than a drug, effectively addressing the core issues of diabetes and metabolic failure. By replicating normal physiological processes, the Micro Dose System (MDS) significantly reduces insulin resistance, enhancing the absorption of blood sugar into cells and its conversion into energy.
Pradeep Mahajan, a leading expert in regenerative medicine at Stemrx Biosciences, is set to travel to Houston, Texas, for a state-of-the-art medical training session. This visit aims to bring this transformative technology to Mumbai, India. The MicroDose System has shown promise in halting the progression of diabetic and metabolic disorders.
"Microdose infusion Therapy represents a significant advancement in the treatment of diabetes and its related disorders," stated Pradeep Mahajan. "By addressing the root cause of metabolic failure, we are not just managing symptoms but potentially reversing the disease's progression."
MicroDose Infusion Therapy targets the underlying causes of diabetes by mimicking natural physiological processes, thereby significantly reducing insulin resistance and improving the absorption and conversion of blood sugar into energy. This novel technique is also effective in managing diabetes-related disorders such as cardiovascular disease, neuropathy, nephropathy, retinopathy, and peripheral artery disease.
Pancreatic β-cells are vital in maintaining glucose homeostasis by secreting insulin, the only hormone capable of lowering blood glucose levels. Impaired insulin secretion leads to chronic hyperglycemia, a hallmark of type 2 diabetes (T2DM), affecting over 450 million people globally. The oscillatory release of insulin and glucose is essential for metabolic balance. In diabetes patients, malfunctioning pancreatic β-cells result in hepatic insulin resistance and the progression of type 2 diabetes.
"The goal of this technology is to mimic the body's natural insulin response, thereby improving overall health and quality of life for patients," added Dr. Mahajan. "Our upcoming training in Houston is a crucial step in bringing this revolutionary treatment to patients in Mumbai."
Common medications and lifestyle modifications often fail to fully address the long-term complications of diabetes, as they do not restore the natural periodic cycle of insulin in healthy physiology. The Micro Dose System, however, has shown promising results in improving bodily functions and halting the progression of chronic diseases related to diabetes. The oscillatory burst release of insulin in this therapy is achieved through a medical device that delivers insulin in a pattern mimicking the body's natural response.
Mahajan's visit aims to bridge the gap between traditional diabetes treatments and advanced regenerative medicine. By introducing Micro Dose Infusion Therapy to India, Stemrx Biosciences hopes to offer patients a revolutionary alternative that targets the root cause of diabetes, providing hope for better health and improved quality of life, the press statement added.
